Tianjin Tianyao Pharmaceuticals announced that the company recently received the DMF First Adequate Letter issued by the US Food and Drug Administration, involving the active pharmaceutical ingredient Di Fu Ke Te. Di Fu Ke Te is a third-generation glucocorticoid widely used in the treatment of Duchenne muscular dystrophy.
津药药业：地夫可特原料药获FDA DMF FA Letter
Tianjin Tianyao Pharmaceuticals: FDA DMF FA Letter for Di Fu Ke Te Active Pharmaceutical Ingredient.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated